The Federal Trade Commission announced Feb. 7 the filing of a complaint against Shire ViroPharma in federal district court.
The FTC alleges the defendants violated antitrust laws by abusing government processes to delay generic competition to its branded prescription drug, Vancocin HCl capsules.
The Federal Drug Administration (FDA) has a practice where it refrains from approving generic applications of a drug if there are any pending citizen petition filings. ViroPharma purportedly used this to its advantage and submitted 43 filings with the FDA to delay the process for generic versions of its drug.
“I have long advocated that the commission target abuses of government processes that significantly harm competition and consumers. The commission’s action is another example of this ongoing commitment,” said FTC acting chairwoman Maureen K. Ohlhausen.
Full Content: Legal News Line
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Geradin Partners Expands Paris Office with Key Hire
Aug 30, 2024 by
CPI
Judge Accuses Google of ‘Clear Abuse’ in Antitrust Case Over Deleted Employee Chats
Aug 29, 2024 by
CPI
Hong Kong Cleaning Company Employee Charged in Historic Antitrust Investigation Case
Aug 29, 2024 by
CPI
Inside the Yelp Suit: Allegations of Google’s Abuse of Search Power
Aug 29, 2024 by
CPI
AI Safety Bill Clears Hurdle in California, Heads to Governor’s Desk
Aug 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – State Attorneys General
Aug 22, 2024 by
CPI
CPI Talks… …With Attorney General Phil Weiser
Aug 22, 2024 by
CPI
The Bipartisan Miracle of State Antitrust Enforcement
Aug 22, 2024 by
Gwendolyn J. Lindsay Cooley
Recent Developments in State Antitrust Enforcement: Agriculture and Food Markets
Aug 22, 2024 by
Elizabeth R. Odette
State Attorneys General: Stewards of Consumer Health and Welfare
Aug 22, 2024 by
Brooke Howlett Lovrovich